All In Biotech

Drug Trial Radar · NCT05959239

TB006 Expanded Access (EA) Compassionate Use

Expanded Access With TB006 Treatment in Adults With Alzheimer's Disease and Related Dementias

Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
TrueBinding, Inc.Industry
Sponsor type
Industry
First posted
Jul 25, 2023

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 55 years

Summary

As written by the sponsor on the registry.

This is an open-label, expanded access, compassionate use treatment protocol of TB006 treatment in participants who meet clinical diagnostic criteria for Alzheimer's disease (AD). Participants will receive TB006 at a dose of 4,000 milligrams (mg) intravenous (IV) over 1 hour every 28 days ± 5 days.

Conditions

  • Alzheimer Disease

Interventions

  • TB006Drug

    TB006 will be provided as single-use injectable glass vials.

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.